TempraMed Receives First Commercial Order from Israel Distributor and Completes Initial Shipment Enabling Entry into National Pharmacy Network
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce its first commercial order in Israel and the successful delivery of an initial shipment to the warehouse of Guri A.A.O. ("Guri"), a leading Israeli medical distribution company.
Technology, Biotechnology, Pharmaceuticals, Health
2026-01-06 5:00 PM EST | TempraMed Technologies Ltd
Moss Genomics Reports Bitcoin Cash (BCH) Mining Activity
Vancouver, British Columbia--(Newsfile Corp. - January 5, 2026) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") has announced it has mined a block on the Bitcoin Cash ("BCH") blockchain using proprietary mining infrastructure operated by the Company. BCH block #931,986 was mined on Jan 1, 2026 with miner ID "MOSS" included in the coinbase signature. This mining activity represents the Company's first operation in the Bitcoin ecosystem. As a team with
2026-01-05 9:29 AM EST | Moss Genomics Inc.
PharmaDrug Completes Acquisition of Initial 19.9% Interest in Canurta Inc. and Completes Debt Restructuring
Toronto, Ontario--(Newsfile Corp. - January 5, 2026) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is pleased to announce that it has closed the previously announced (see press release dated October 31, 2025) acquisition (the "Transaction") of limited partnership units of Canurta Limited Partnership ("Canurta"), the p
Biotechnology, Cannabis, Psychedelics, Cannabis Manufacturer
2026-01-05 8:00 AM EST | PharmaDrug Inc.
OS Therapies Provides First Half 2026 Corporate Outlook
Company finalizing preparations for end of January 2026 U.S. FDA Biologics License Application (BLA) submission for OST-HER2 program in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma (Metastatic Osteosarcoma Program) under Accelerated Approval Program Biomarker data from Phase 2b Metastatic Osteosarcoma Program human clinical trial expected to be released during week of J.P. Morgan Healthcare Conference 202
2026-01-05 7:40 AM EST | OS Therapies
CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accelerate Medical Cannabis Research in the Schedule III Transition
Houston, Texas--(Newsfile Corp. - January 5, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced the launch of a national outreach and partnership initiative designed to capitalize on the accelerating federal momentum toward moving cannabis from Schedule I to Schedule III through the ongoing rescheduling rulemaking process. On December 18, 2025, a Presidential Exe
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-01-05 7:00 AM EST | Cannabis Bioscience International Holdings
TempraMed Provides Positive Recap on 2025 and Strategic Outlook for 2026
Vancouver, British Columbia--(Newsfile Corp. - January 2, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide a positive recap on the year as well as a strategic outlook for the year ahead in 2026. As 2025 ends, the Company reflects on a transformative year marked by significant commercial progress, strategi
Technology, Biotechnology, Pharmaceuticals, Health
2026-01-02 5:00 PM EST | TempraMed Technologies Ltd
PharmaTher CEO Publishes Letter to Shareholders
Toronto, Ontario--(Newsfile Corp. - January 2, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher") today announced that CEO Fabio Chianelli has published a letter to shareholders. Dear Shareholders, With 2025 complete, I want to thank you for your continued support of PharmaTher. This past year marked a shift from ambitious development to concrete validation, setting the stage for what I believe will be a value-unlocking year ahead
Biotechnology, Pharmaceuticals
2026-01-02 8:00 AM EST | PharmaTher Holdings Ltd.
TempraMed Deepens Asian Market Penetration with Expanded Distribution Partnership and Meaningful Commercial Order in South Korea
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce today a new commercial order and an extension of its distribution partnership in South Korea. The expanded collaboration with Mavericks Co. Ltd ("Mavens"), a South Korea–
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-31 5:00 PM EST | TempraMed Technologies Ltd
Izotropic Announces AGM Results
British Columbia and Sacramento, California--(Newsfile Corp. - December 31, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the results of its Annual General and Special Meeting held on December 29, 2025. Company mat
2025-12-31 4:31 PM EST | Izotropic Corporation
Hemostemix Closes $480,000 Private Placement at $0.12 per Share
Calgary, Alberta--(Newsfile Corp. - December 31, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (the "Company" or "Hemostemix"), an autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, total body ischemia, and vascular dementia, is pleased to announce that it has closed a non-brokered private placement for aggregate gross proceed
Biotechnology, Pharmaceuticals, Health
2025-12-31 2:38 PM EST | Hemostemix Inc.
BioMark: 2025 Achievements & 2026 Vision
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, today issued a Year-End Letter to Shareholders and Team from its Chief Executive Officer and Founder, Rashid Ahmed Bux. Dear BioMark Shareholders and Team, As we reflect on 2025, we celebrate a transformative year that positions B
Technology, Biotechnology, Healthcare and Hospitals
2025-12-31 8:30 AM EST | BioMark Diagnostics, Inc.
BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - December 30, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that Mr. James Lavender has joined the BioMark Board of Directors. His appointment follows resolutions accepted during the Company's Annual General Meeting (AGM) held on December 22nd, 2025. Mr. Lavender and his group we
Technology, Biotechnology, Healthcare and Hospitals
2025-12-30 8:30 AM EST | BioMark Diagnostics, Inc.
CBIH Announces New Patent Initiative Targeting Opioid Addiction Through Endocannabinoid Pathways
Houston, Texas--(Newsfile Corp. - December 29, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced that it is pursuing a new patent for an investigational therapy designed to address opioid addiction, a condition that continues to claim tens of thousands of lives each year in the United States. According to U.S. public health data, more than 700,000 people have died
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-12-29 7:00 AM EST | Cannabis Bioscience International Holdings
TempraMed Launches New Product, VIVI Cap Smart, Expanding Its Portfolio to Include a Digital Health Offering
Highlights: Expands TempraMed's product portfolio and adds a digital component to track and record medication use. First in the world platform that turns almost every insulin and GLP-1 pens to be connected and with a temperature shield. Unlocks significant pharma, healthcare provider, and real-time data opportunity to track compliance, efficacy, side effects, and other important information. Adds subscription-based business model to produ
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-26 5:00 PM EST | TempraMed Technologies Ltd
Theralase(R) Closes $1.3 M Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - December 23, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement offering ("Offering") of units ("Units"). On
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-12-23 4:40 PM EST | Theralase Technologies Inc.
A Year of Purpose and Progress: Dr. Christina Rahm Celebrates Global Growth, Scientific Breakthroughs, and International Honors
Franklin, Tennessee--(Newsfile Corp. - December 23, 2025) - From global stages and scientific breakthroughs to philanthropic leadership and international recognition, 2025 has marked a defining year for Dr. Christina Rahm. As Chief Science Officer of The ROOT Brands and founder of DRC Ventures, Dr. Rahm continues to lead at the intersection of science, sustainability and purpose-driven innovation. Her work this year has expanded far beyond the laboratory, spanning continents, empowering commu
Biotechnology, Food / Beverages, Health
2025-12-23 11:41 AM EST | DRC Ventures
Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01
Calgary, Alberta--(Newsfile Corp. - December 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, total body ischemia, vascular dementia, is pleased to announce the appointment of Dr. David B. Alper, DPM, FFPM RCPS, to a lead role as Multidisciplinary Physic
Biotechnology, Pharmaceuticals, Health
2025-12-23 9:10 AM EST | Hemostemix Inc.
Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it has taken a
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-12-23 8:45 AM EST | Phio Pharmaceuticals Corp.
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program
Vancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that it has officially initiated its ISO 15189 accreditation program with the Standards Council of Canada (SCC) for its medical laboratory in Quebec City. The accreditation process officially commenced on December 19, 2025. BioMark has engaged the Standards
Technology, Biotechnology, Healthcare and Hospitals
2025-12-23 8:30 AM EST | BioMark Diagnostics, Inc.
Restart Life Receives Aggregate Gross Proceeds of Approximately $590,000 from Warrant Exercises and Loan
Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that it has received aggregate gross proceeds of approximately CAD$590,000 through the exercise of previously issued common share purchase warrants and the closing of a corporate loan. The Company reports that holders of previously issued warrants exercised an aggregate of 4,103,023 warrants for
Technology, Biotechnology, Health
2025-12-22 12:00 PM EST | Restart Life Sciences Corp.